DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05875636

Completed

GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

260

actual

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Retained gastric food

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05875636
Org study IDPro00129059

Timeline

Milestones

Study first posted2023-05-25actual
Study start2023-08-21actual
Primary completion2024-08-23actual
Study completion2024-08-23actual
Last update posted2024-09-19actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

This study will consist of patients who have appropriately fasted, and are scheduled for an esophagogastroduodenoscopy (EGD). Patients will fall in to two groups: 1) taking a GLP-1 receptor agonist or 2) not taking a receptor agonist medication.

Inclusion criteria

•Adults 18 years of age and older presenting for esophagogastroduodenoscopy (EGD)
•One of the following groups:
–GLP-1 receptor agonist cohort: active treatment with any GLP-1 receptor agonist therapy within prior 30 days
–Control cohort: not taking a GLP-1 receptor agonist medication
•Appropriately fasted per ASA Fasting Guidelines

Exclusion criteria

•Simultaneous bowel preparation/planned dual endoscopy with colonoscopy
•Any pre-planned alteration to standard fasting guidelines (ASA NPO guidelines)
•Emergency endoscopic procedure
•Concern for active GI bleeding
•Food impaction/foreign body as indication for procedure
•Gastric outlet obstruction/bowel obstruction
•Achalasia
•Zenker's diverticulum
•History of esophageal or gastric surgery
•Active pregnancy
•Chronic daily opioid therapy ≥ 15 MMEs per day
•Prokinetic agent use (i.e. metoclopramide)
•Inability or unwillingness of subject to give informed consent

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Retained gastric food

Time frame:From time of enrollment until the end of surgery, assessed up to 4 weeks

threshold achievement, event

Secondary/protocol endpoint

Incidence of pulmonary aspiration event

Time frame:From the time surgery begins until the end of scheduled surgery, assessed up to 24 hours

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.